Praxis Precision Medicines Provides Corporate Update Including Highlights of Movement Disorders Studies

Posted on August 26, 2021

CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) —¬†Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Categories: In the News